Pharmacological and Pharmaceutical Profile of Gliclazide: A Review.
Loading...
Date
2011-11
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Gliclazide is a second generation sulphonylurea oral hypoglycaemic agent used in the
treatment of non-insulin-dependent diabetes mellitus (NIDDM). It improves defective insulin
secretion and may reverse insulin resistance observed in patients with NIDDM. These actions are
reflected in a reduction in blood glucose levels which is maintained during both short and long
term administration, and is comparable with that achieved by other sulphonylurea agents.
Gradually accumulating evidence suggests that gliclazide may be useful in patients with diabetic
retinopathy, due to its haemobiological actions, and that addition of gliclazide to insulin therapy
enables insulin dosage to be reduced. Thus, gliclazide is an effective agent for the treatment of the
metabolic defects associated with NIDDM and may have the added advantage of potentially
slowing the progression of diabetic retinopathy. These actions, together with its good general
tolerability and low incidence of hypoglycaemia have allowed gliclazide to be well placed within
the array of oral hypoglycaemic agents available for the control of NIDDM.
Description
Keywords
Gliclazide, oral hypoglycaemic agent, diabetes mellitus, tolerability, diabetic retinopathy
Citation
Sarkar Ananya, Tiwari Ajay, Bhasin Parminder S, Mitra Moloy. Pharmacological and Pharmaceutical Profile of Gliclazide: A Review. Journal of Applied Pharmaceutical Science. 2011 Nov; 1(9): 11-19.